Drug class
Cyclic Pyranopterin Monophosphate
Mechanism of action
Patients with MoCD Type A have mutations in the MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP.
General use cases
- Metal Metabolism, Inborn Errors
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
